Literature DB >> 25100370

Clinical profile of nonalcoholic Fatty liver disease among young patients with type 1 diabetes mellitus seen at a diabetes speciality center in India.

Ramanujam Vendhan1, Anandakumar Amutha1, Ranjit Mohan Anjana1, Ranjit Unnikrishnan1, Viswanathan Mohan1.   

Abstract

OBJECTIVE: To estimate the prevalence and clinical profile of nonalcoholic fatty liver disease (NAFLD) among young type 1 diabetes mellitus (T1DM) patients at a tertiary care diabetes center in India.
METHODS: Electronic medical records of T1DM patients (age at first diagnosis of T1DM ≤25 years) registered between January 1992 and May 2013 who had undergone ultrasonography and denied history of any alcohol intake (n = 736) were reviewed. NAFLD was diagnosed if there was any degree of fatty liver. Retinopathy was initially assessed by direct and indirect ophthalmoscopy and later by retinal photography. Nephropathy was diagnosed if urine protein excretion was >500 mg/day, and neuropathy was diagnosed if a patient's vibration perception threshold on biothesiometry was ≥20 V.
RESULTS: A total of 204/736 (27.7%) T1DM patients had NAFLD. Compared to T1DM subjects without NAFLD those with NAFLD had higher body mass index (BMI) (18.9 ± 4.2 vs. 20.2 ± 4.7 kg/m2, P<.001), waist circumference (67.9 ± 13.2 vs. 71.9 ± 13.3 cm, P<.05), systolic blood pressure (110 ± 15 vs. 116 ± 18 mm Hg, P<.001) and diastolic blood pressure (72 ± 9 vs. 74 ± 10 mm Hg, P<.05), while fasting blood glucose (201 ± 101 vs. 183 ± 101 mg/dL, P<.05) and alkaline phosphatase (419 [12.5] vs. 315 [15.8], P<.001) levels were lower in patients with T1DM with NAFLD. Multiple logistic regression analysis showed a significant association between NAFLD and retinopathy (odds ratio [OR]: 2.01, 95% confidence interval [CI]: 1.13-3.43; P = .017, after adjusting for sex, duration of diabetes, overweight/obesity, hypertension, fasting plasma glucose, nephropathy, and nephropathy (OR: 1.89, 95% CI: 1.02-3.50; P = .042), after adjusting for sex and fasting plasma glucose.
CONCLUSIONS: This study suggests that NAFLD is also seen among T1DM patients and that it has an independent and significant association with retinopathy and nephropathy.

Entities:  

Mesh:

Year:  2014        PMID: 25100370     DOI: 10.4158/EP14044.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  6 in total

1.  Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Authors:  Marieke de Vries; Jan Westerink; Karin H A H Kaasjager; Harold W de Valk
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

Review 2.  Beyond the Liver: Liver-Eye Communication in Clinical and Experimental Aspects.

Authors:  Tian-Hao Yuan; Zhen-Sheng Yue; Guo-Heng Zhang; Lin Wang; Guo-Rui Dou
Journal:  Front Mol Biosci       Date:  2021-12-24

3.  Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes.

Authors:  Sahar Samimi; Sahar Rajabzadeh; Soghra Rabizadeh; Manouchehr Nakhjavani; Pooria Nakhaei; Foroogh Alborzi Avanaki; Alireza Esteghamati
Journal:  Eur J Med Res       Date:  2022-07-11       Impact factor: 4.981

4.  Allopurinol ameliorates liver injury in type 1 diabetic rats through activating Nrf2.

Authors:  Fei Zeng; Jierong Luo; Hong Han; Wenjie Xie; Lingzhi Wang; Ronghui Han; Hao Chen; Yin Cai; Huansen Huang; Zhengyuan Xia
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

5.  Enhancement of Adiponectin Ameliorates Nonalcoholic Fatty Liver Disease via Inhibition of FoxO1 in Type I Diabetic Rats.

Authors:  Xiang Xie; Dan Yan; Haobo Li; Qiqi Zhu; Jun Li; Yong-Ping Fang; Chi Wai Cheung; Michael G Irwin; Zhengyuan Xia; Qingquan Lian
Journal:  J Diabetes Res       Date:  2018-08-16       Impact factor: 4.011

6.  Liver fibrosis is independently associated with diabetic peripheral neuropathy in type 2 diabetes mellitus.

Authors:  Jinya Huang; Rumei Li; Naijia Liu; Na Yi; Hangping Zheng; Qi Zhang; Lianying Zhou; Linuo Zhou; Renming Hu; Bin Lu
Journal:  J Diabetes Investig       Date:  2021-08-08       Impact factor: 4.232

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.